Pharnext naar beleggersconferenties in november
PARIJS–(BUSINESS WIRE)–
Pharnext SA (FR0011191287 – ALPHA) (PariJs:ALPHA), een biofarmaceutisch bedrijf met een vernieuwende benadering van geneesmiddelen door reeds bekende medicijnen te combineren en te herpositioneren, heeft vandaag bekendgemaakt dat zijn directie in november de volgende conferenties in Europa bezoekt:
- BIO-Europe® 20171, op 6-8 november 2017 in CityCube Berlin, in Berlijn, Duitsland
- Jefferies 2017 London Healthcare Conference2 op 16 november in Londen, Verenigd Koninkrijk.
- Actionaria3,Individuals shareholders exhibition op 23-24 november 2017 in Palais des Congrès, Frankrijk
- Bedrijfspresentatie: tijdens “Facing the leaders” op 23 november, van 15.45 tot 16.00 CET. Spreker : Mr. Olivier Legrand, Pharnext.
- Geneva European Midcap Event4 op 28 november 2017 in Genève, Zwitserland.
Pharnext to Attend November Investors Conferences
PARIS–(BUSINESS WIRE)– Regulatory News:
Pharnext SA (FR0011191287 – ALPHA)(Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that senior management will be attending the following conferences taking place in November 2017 throughout Europe.
- BIO-Europe® 20171, on November 6-8, 2017 at CityCube Berlin, Berlin, Germany.
- Jefferies 2017 London Healthcare Conference2 on November 16, 2017 in London, United Kingdom.
- Actionaria3,Individuals shareholdersexhibition on November 23-24, 2017 at Palais des Congrès, Paris, France.
- Corporate Overview Presentation: during “Facing the leaders” on November 23, from 3:45pm to 4:00pm CET. Speaker : Mr. Olivier Legrand, Pharnext.
- Geneva European Midcap Event4 on November 28, 2017 in Geneva, Switzerland.
If you are interested in meeting the Pharnext management team during either of these events or if you need more information about Pharnext’s participation, please send an email to investors@pharnext.com.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
1https://ebdgroup.knect365.com/bioeurope/about-bio-europe
2http://www.jefferies.com/OurFirm/Conferences/325/352
3http://www.actionaria.com/
4http://www.midcapevents.com/geneva2017/home/
View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005049/en/
Contacts
Pharnext
Xavier Paoli, +33 (0)1-4109-2230
VP, Chief Commercial Officer
contact@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1-212-362-1200
matthew@sternir.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1-5688-1115
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Aurore Gangloff
pharnext@alizerp.com
+33 (0)1-4454-3664
or
Media Relations (U.S.)
RooneyPartners
Marion Janic, +1-212-223-4017
mjanic@rooneyco.com